VA launches nationwide precision cancer program for veterans
S. 4993 — POPCaP Act of 2026 · Filed by Jerry Moran (R-KS) · 1 cosponsor · Introduced Jul 15, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the VA to establish a precision oncology program for prostate cancer, designating 28 specific VA medical centers as centers of excellence to provide genetic sequencing, clinical trials, and coordinated care for veterans with prostate cancer. The program includes a central leadership team, mandatory staffing requirements (oncologists, radiologists, urologists, pathologists, researchers), and $15.5 million in annual funding through 2029, with annual reporting to Congress on outcomes and survival rates.
Why we flagged it
The bill establishes a new specialized cancer treatment program within the VA system, expanding clinical services and research infrastructure for a specific veteran population. It is a straightforward public health initiative with no hidden mechanisms or private carve-outs.
What the text implies
- The bill locks in 28 specific VA facilities as centers of excellence for at least 5 years (through 2032), limiting the Secretary's flexibility to reallocate resources or close underperforming centers until 2030 at earliest.
- Mandatory staffing requirements (medical oncologist, interventional radiologist, urologist, radiation oncologist, pathologist, two research staff) may strain recruitment at rural or lower-tier VA facilities, potentially creating geographic disparities in program quality.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies (precision oncology drug developers); biotech firms (genetic sequencing and biomarker testing providers); clinical research organizations (contract research services)